As demonstrated in vivo, p53 cancermutants can be reactivated through intragenic second-site suppressor(“cancer rescue”) mutations [13]–[15].Reactivated p53 holds great therapeutic promise because animal models have shownthat reintroduction of active p53, even in advanced tumors, leads to tumorregression [16]–[18]. The gene discussed is TP53; the disease is cancer.